Energy Boost For Fatigued Cancer PatientsJune 11, 2002
SWALLOWING a specially designed energy drink each day could boost cancer patients left exhausted by chemotherapy, according to research published in the British Journal of Cancer today* (Tuesday).
Fatigue is one of the most common side effects of treatment for cancer, robbing patients of the energy to perform everyday tasks and severely impairing their quality of life.
But Italian scientists have found that giving people a substance called levocarnitine - which is taken in a pineapple flavoured drink - seems to help them recover from the effects of treatment. In their study, 90 per cent of those who received the supplement recovered from their fatigue within a week.
Scientists believe many cases of fatigue - which affects 80 per cent of patients receiving chemotherapy - occur when treatment disrupts a patient's metabolism. This depletes levels of a molecule called carnitine, which is vital for providing energy to our muscles.
Lead researcher Dr Francesco Graziano, of Urbino Hospital in Italy, comments: "After chemotherapy, many patients have low levels of carnitine in their blood and we think that's one of the reasons they feel so exhausted. It seemed logical that boosting carnitine levels with a dietary supplement might restore that lost energy. Our study was the first to take this new approach to treating fatigue and the results, although preliminary, were very encouraging."
Dr Graziano and his colleagues studied 50 patients who had reported feeling fatigue during the course of their chemotherapy. They used detailed questionnaires to assess each patient's degree of fatigue and took blood samples to measure carnitine levels.
Researchers then gave patients an energy drink containing levocarnitine, which is converted to carnitine in the body. After a week of treatment, their progress was assessed.
On average, blood carnitine levels increased by 50 per cent over the course of the week. And the questionnaires revealed that 45 of the 50 patients (90 per cent) no longer felt fatigued.
Dr Graziano adds: "The quality of life of our patients improved markedly over the course of the week, and it seems likely that the improvements were a result of the supplements they were taking.
"We now need larger-scale trials, to test the extent to which the supplement can restore patients' energy levels. It could become an important way of maintaining quality of life for patients undergoing intensive treatment for cancer."
Prof Gordon McVie of Cancer Research UK, owners of the British Journal of Cancer, says: "Treating patients more effectively doesn't just mean keeping them alive for longer; it also means preserving their quality of life.
"We are getting better at reducing the side effects associated with modern drugs, but chemotherapy still robs many patients of the energy they need to live their life to the full. A simple dietary supplement to restore a patient's zip would be a valuable step forward and these initial results are certainly encouraging."
Cancer Research UK
Related Chemotherapy Current Events and Chemotherapy News Articles
Modified microalgae converts sunlight into valuable medicine
Researchers from Copenhagen Plant Science Centre at University of Copenhagen have succeeded in manipulating a strain of microalgae to form complex molecules to an unprecedented extent.
Identification of a chemotherapy resistance factor in breast cancer patients
Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 (HER2).
Two-pronged attack on chemotherapy-resistant leukemia cells
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer in Switzerland. Despite intensive chemotherapy, one fifth of the patients suffer a relapse, which usually goes hand in hand with a poor prognosis.
New drug combination shows promise for resistant leukemia
Patients with acute myeloid leukaemia (AML) can look forward to the development of new therapies following the discovery by Walter and Eliza Hall Institute researchers of a new way to kill cells that are dangerously multiplying.
Altered brain connectivity may explain cognitive impairment in pediatric leukemia survivors
The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information.
Blocking apoptotic response could preserve fertility in women receiving cancer treatments
Female cancer patients of reproductive age could preserve their fertility during radiation and chemotherapy through treatments that target the DNA damage response in oocytes (the cells that develop into eggs), an approach that works in animal models.
Experimental drug against hepatitis C slows down Zika virus infection in mice
Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy.
Cisplatin may cause more permanent hearing loss in people with Cockayne syndrome
The chemotherapy drug cisplatin can kill cancer, but it can also cause permanent hearing loss.
Targeted antibiotic is easier on the gut microbiome
A targeted antibiotic designed for treatment of staph infections caused fewer changes to the gut microbiome of mice than did common broad-spectrum antibiotics.
Modeling and simulation help optimize chemotherapy to combat brain tumor
St. Jude Children's Research Hospital scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a successful phase I clinical trial of a chemotherapy agent for treatment of ependymoma.
More Chemotherapy Current Events and Chemotherapy News Articles